secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-08-05T13:27:18+00:00
Accession:  0001213900-26-085432
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology: new institutional accounts ordering LYMPHIR up 78% QoQ
-----------------------------------------------------------------------

- New institutions ordering LYMPHIR increased 78% in Q2 2026 vs. prior quarter; total vial orders up 31%.
- LYMPHIR now available in 42 institutions including academic and NCCN centers.
- Near-universal payer coverage achieved; initial CTCL market exceeds $400 million.
- Company expects >20 additional institutions in current quarter, targeting 100 priority institutions by year-end.
- Wholesaler reorders have begun reflecting increased institutional demand; revenue recognized on filled wholesale orders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/0001213900-26-085432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/ea0300373-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-085432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer